Primary-source record
Decision-gradeTopline results
Mirum to Report Phase 3 EXPAND Topline Results for LIVMARLI (maralixibat)
Mirum will host an investor call on October 12, 2026 to share topline results from the Phase 3 EXPAND study of LIVMARLI (maralixibat) in ultra-rare cholestatic liver diseases. This is the first disclosure of the primary efficacy and safety data from the randomized, placebo-controlled trial evaluating cholestatic pruritus in patients 6 months and older, including those with biliary atresia.
Key facts
- Filed
- Oct 13, 2026, 12:09 PM
- Event
- Topline results
- Direction
- Neutral
- Company
MIRMMirum- Asset
- maralixibat
- Source
- SEC 8-K
- Confidence
- Sourced
- enrolled
- 52
- sBA reduction
- -70.1% vs -3.5% (effect -69.0%, p<0.0001)
- BA subgroup itch
- -2.16 vs -1.01 (diff -1.15, p=0.0002)
- primary endpoint
- -1.81 vs -0.83 (diff -0.98, p=0.0004)
Source excerpt
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, October 12, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the Phase 3 EXPAND study evaluating LIVMARLI ® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia. Conference Call Details: US/Toll-Free: +1 833 461 5787 International: +1 585 542 9983 Access Code: 486697901 You may also access the call via webcast by visiting the Investors section of Mirum’s corporate website. The archived webcast will be available for replay. About Mirum Pharmaceuticals Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum foc